Ophthalmology Department, University of Bari, Bari, Italy.
J Ocul Pharmacol Ther. 2012 Oct;28(5):536-41. doi: 10.1089/jop.2012.0021. Epub 2012 Jun 25.
Tight control of intraocular pressure (IOP) is still the only therapeutic approach available for the treatment of primary open angle glaucoma (POAG). However, some patients do not respond adequately to hypotonising drugs, and despite multiple drug combinations they cannot reach their target IOP. Forskolin is a natural compound that has already shown efficacy in IOP reduction following topical application.
The aim of this study was to evaluate the effects on the IOP of a food supplement containing forskolin and rutin when administered to POAG patients under maximum tolerated medical therapy (MTMT) and on a waiting list for filtrating surgery to further decrease their IOP.
The design of the study was open and case-controlled. Ninety-seven (52 in the treatment group, and 45 in the reference group) patients were enrolled in 8 different glaucoma centers in Italy, all under MTMT and with IOP enrollment values above their target pressure. During the 30 days before surgery, patients in the treatment group were prescribed 2 tablets per day of a food supplement containing rutin and forskolin in addition to their usual topical drug treatment. Their IOP values were measured at 3 time points during the day, at enrollment and once a week until surgery. Control patients continued only with their normal topical therapy.
All patients in the treatment group, independently of the combination drug therapy that they were taking, showed a further 10% decrease (P<0.01) of their IOP, starting from 1 week after introduction of the oral supplement and lasting until the last evaluation before surgery. This decrease was more evident (15% of the enrollment value; P<0.01) in those subjects with high (IOP≥21 mmHg) enrollment values rather than in those with low (IOP<21) enrollment values (9%; P<0.01). On the contrary, IOP values in the control group remained stable from the beginning to the end of the observation period, independently of their enrollment values.
Forskolin and rutin given as oral treatment appear to contribute to a better control and a further small reduction of IOP in patients who were poorly responsive to multitherapy treatment.
尽管通过降低眼压(IOP)的治疗方式仍是治疗原发性开角型青光眼(POAG)的唯一方法,但仍有部分患者对降眼压药物反应不佳,尽管采用了多种药物联合治疗,但仍无法达到目标眼压。福司可林是一种天然化合物,其在局部应用降低眼压方面已显示出疗效。
本研究旨在评估含有福司可林和芦丁的膳食补充剂对最大耐受药物治疗(MTMT)下 POAG 患者眼压的影响,以及对等待滤过性手术的患者进一步降低眼压的影响。
本研究为开放和病例对照设计。97 名(治疗组 52 名,对照组 45 名)患者在意大利的 8 个不同青光眼中心参与研究,他们都处于 MTMT 阶段,IOP 值高于目标压力。在手术前 30 天,治疗组患者每天服用 2 片含有芦丁和福司可林的膳食补充剂,同时继续使用局部药物治疗。治疗组患者在日间的 3 个时间点、入组时和每周一次测量 IOP 值,直至手术。对照组患者仅继续使用其常规的局部治疗。
治疗组所有患者(无论他们正在使用何种联合药物治疗)在开始口服补充剂后 1 周,且持续到手术前最后一次评估,其 IOP 进一步下降了 10%(P<0.01)。与低(IOP<21)入组值患者相比(9%;P<0.01),高(IOP≥21mmHg)入组值患者的降幅更为显著(IOP 下降值为入组值的 15%;P<0.01)。相反,对照组患者的 IOP 值从开始到观察结束保持稳定,与入组值无关。
福司可林和芦丁口服治疗可能有助于更好地控制眼压,并进一步降低对多疗法治疗反应不佳的患者的眼压。